Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD

29.83  -0.38 (-1.26%)

After market: 29.83 0 (0%)

Fundamental Rating

6

Taking everything into account, AMPH scores 6 out of 10 in our fundamental rating. AMPH was compared to 193 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes AMPH very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
AMPH had positive earnings in each of the past 5 years.
In the past 5 years AMPH always reported a positive cash flow from operatings.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

AMPH's Return On Assets of 8.71% is amongst the best of the industry. AMPH outperforms 92.23% of its industry peers.
The Return On Equity of AMPH (18.85%) is better than 92.23% of its industry peers.
With an excellent Return On Invested Capital value of 11.31%, AMPH belongs to the best of the industry, outperforming 89.64% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 14.76%.
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROIC 11.31%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

AMPH has a better Profit Margin (19.38%) than 93.26% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 26.65%, AMPH belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
AMPH's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 50.50%, AMPH is doing good in the industry, outperforming 64.25% of the companies in the same industry.
AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMPH is still creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
The number of shares outstanding for AMPH has been increased compared to 5 years ago.
Compared to 1 year ago, AMPH has an improved debt to assets ratio.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 2.62 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of AMPH (2.62) is better than 68.39% of its industry peers.
AMPH has a debt to FCF ratio of 4.02. This is a neutral value as AMPH would need 4.02 years to pay back of all of its debts.
AMPH has a better Debt to FCF ratio (4.02) than 88.08% of its industry peers.
AMPH has a Debt/Equity ratio of 0.80. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.80, AMPH is not doing good in the industry: 68.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Altman-Z 2.62
ROIC/WACC1.18
WACC9.6%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.95 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Current ratio of 2.95. This is comparable to the rest of the industry: AMPH outperforms 52.85% of its industry peers.
A Quick Ratio of 2.02 indicates that AMPH has no problem at all paying its short term obligations.
With a Quick ratio value of 2.02, AMPH perfoms like the industry average, outperforming 45.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.02
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

AMPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.47%.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
Looking at the last year, AMPH shows a quite strong growth in Revenue. The Revenue has grown by 13.59% in the last year.
The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%

3.2 Future

The Earnings Per Share is expected to decrease by -0.72% on average over the next years.
AMPH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.44% yearly.
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue Next Year-1.23%
Revenue Next 2Y2.1%
Revenue Next 3Y2.52%
Revenue Next 5Y4.44%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

AMPH is valuated reasonably with a Price/Earnings ratio of 8.60.
Based on the Price/Earnings ratio, AMPH is valued cheaper than 91.71% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.93. AMPH is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 8.19, which indicates a very decent valuation of AMPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 87.05% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AMPH to the average of the S&P500 Index (35.31), we can say AMPH is valued rather cheaply.
Industry RankSector Rank
PE 8.6
Fwd PE 8.19
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AMPH is valued cheaply inside the industry as 92.23% of the companies are valued more expensively.
AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 92.23% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.36
EV/EBITDA 6.86
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.14
EPS Next 2Y-2.84%
EPS Next 3Y0.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (8/15/2025, 4:30:00 PM)

After market: 29.83 0 (0%)

29.83

-0.38 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners72.89%
Inst Owner Change-1.17%
Ins Owners9.16%
Ins Owner Change6.71%
Market Cap1.41B
Analysts76.67
Price Target33.41 (12%)
Short Float %11.13%
Short Ratio8.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.55%
Min EPS beat(2)-4.55%
Max EPS beat(2)5.65%
EPS beat(4)2
Avg EPS beat(4)3.88%
Min EPS beat(4)-4.74%
Max EPS beat(4)19.17%
EPS beat(8)5
Avg EPS beat(8)11.41%
EPS beat(12)8
Avg EPS beat(12)16.64%
EPS beat(16)11
Avg EPS beat(16)20.36%
Revenue beat(2)0
Avg Revenue beat(2)-2.65%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.43%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-0.34%
Revenue beat(12)6
Avg Revenue beat(12)-0.04%
Revenue beat(16)9
Avg Revenue beat(16)0.9%
PT rev (1m)-0.76%
PT rev (3m)-7.09%
EPS NQ rev (1m)-2.4%
EPS NQ rev (3m)2.35%
EPS NY rev (1m)0%
EPS NY rev (3m)0.34%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-2.94%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE 8.6
Fwd PE 8.19
P/S 1.92
P/FCF 9.36
P/OCF 7.28
P/B 1.87
P/tB 8.43
EV/EBITDA 6.86
EPS(TTM)3.47
EY11.63%
EPS(NY)3.64
Fwd EY12.22%
FCF(TTM)3.19
FCFY10.68%
OCF(TTM)4.1
OCFY13.74%
SpS15.5
BVpS15.94
TBVpS3.54
PEG (NY)N/A
PEG (5Y)0.14
Profitability
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROCE 13.64%
ROIC 11.31%
ROICexc 13.56%
ROICexgc 26.64%
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
FCFM 20.56%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexcg growth 3Y24.9%
ROICexcg growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Debt/EBITDA 2.39
Cap/Depr 73.47%
Cap/Sales 5.88%
Interest Coverage 7.56
Cash Conversion 76.31%
Profit Quality 106.07%
Current Ratio 2.95
Quick Ratio 2.02
Altman-Z 2.62
F-Score7
WACC9.6%
ROIC/WACC1.18
Cap/Depr(3y)86.1%
Cap/Depr(5y)106.5%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.47%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-9.57%
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue 1Y (TTM)13.59%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-4.38%
Revenue Next Year-1.23%
Revenue Next 2Y2.1%
Revenue Next 3Y2.52%
Revenue Next 5Y4.44%
EBIT growth 1Y-7.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-3.45%
EBIT Next 3Y2.76%
EBIT Next 5Y5.95%
FCF growth 1Y192.27%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y145.14%
OCF growth 3Y29.62%
OCF growth 5Y38.57%